2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
21
Carcinoma, Non-Small-Cell Lung
21
Breast Neoplasms
20
Neoplasms
19
Stomach Neoplasms
15
Colorectal Neoplasms
15
Lung Neoplasms
13
Endometrial Neoplasms
13
Pancreatic Neoplasms
11
Leukemia, Myeloid, Acute
10
Colonic Neoplasms
9
Carcinoma, Hepatocellular
9
Oropharyngeal Neoplasms
6
Neoplasm Metastasis
6
Multiple Myeloma
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Esophageal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Rectal Neoplasms
5
Mouth Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Head and Neck Neoplasms
5
Uterine Cervical Neoplasms
4
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Interventions
Cyclophosphamide
17
ofatumumab
14
fludarabine
11
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
obinutuzumab
5
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
pirtobrutinib
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Observation
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts